A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Int J Clin Oncol
; 27(1): 224-233, 2022 Jan.
Article
in En
| MEDLINE
| ID: mdl-34599726
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Myeloma
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Int J Clin Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Type:
Article
Affiliation country:
Japan